EP3997128A4 - Procédé d'élimination de cellules souches hématopoïétique/progéniteurs hématopoïétiques (csh/ph) chez un patient à l'aide d'anticorps bispécifiques - Google Patents

Procédé d'élimination de cellules souches hématopoïétique/progéniteurs hématopoïétiques (csh/ph) chez un patient à l'aide d'anticorps bispécifiques Download PDF

Info

Publication number
EP3997128A4
EP3997128A4 EP20836912.4A EP20836912A EP3997128A4 EP 3997128 A4 EP3997128 A4 EP 3997128A4 EP 20836912 A EP20836912 A EP 20836912A EP 3997128 A4 EP3997128 A4 EP 3997128A4
Authority
EP
European Patent Office
Prior art keywords
hsc
patient
hematopoietic
stem cells
specific antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP20836912.4A
Other languages
German (de)
English (en)
Other versions
EP3997128A1 (fr
Inventor
Vladislav Sandler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hemogenyx Pharmaceuticals LLC
Original Assignee
Hemogenyx Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/506,764 external-priority patent/US11104738B2/en
Application filed by Hemogenyx Pharmaceuticals LLC filed Critical Hemogenyx Pharmaceuticals LLC
Publication of EP3997128A1 publication Critical patent/EP3997128A1/fr
Publication of EP3997128A4 publication Critical patent/EP3997128A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP20836912.4A 2019-07-09 2020-07-08 Procédé d'élimination de cellules souches hématopoïétique/progéniteurs hématopoïétiques (csh/ph) chez un patient à l'aide d'anticorps bispécifiques Withdrawn EP3997128A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/506,764 US11104738B2 (en) 2016-04-04 2019-07-09 Monoclonal antibodies to human FLT3/FLK2 receptor protein
PCT/US2020/041095 WO2021007266A1 (fr) 2019-07-09 2020-07-08 Procédé d'élimination de cellules souches hématopoïétique/progéniteurs hématopoïétiques (csh/ph) chez un patient à l'aide d'anticorps bispécifiques

Publications (2)

Publication Number Publication Date
EP3997128A1 EP3997128A1 (fr) 2022-05-18
EP3997128A4 true EP3997128A4 (fr) 2023-10-18

Family

ID=74115143

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20836912.4A Withdrawn EP3997128A4 (fr) 2019-07-09 2020-07-08 Procédé d'élimination de cellules souches hématopoïétique/progéniteurs hématopoïétiques (csh/ph) chez un patient à l'aide d'anticorps bispécifiques

Country Status (5)

Country Link
EP (1) EP3997128A4 (fr)
JP (1) JP2022540602A (fr)
CN (1) CN114829399A (fr)
CA (1) CA3146912A1 (fr)
WO (1) WO2021007266A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017219025A1 (fr) * 2016-06-17 2017-12-21 Magenta Therapeutics, Inc. Compositions et méthodes de déplétion de cellules
US20180110832A1 (en) * 2015-04-20 2018-04-26 The Board Of Regents Of The University Of Texas Sy Stem Clec11a is a bone growth agent

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11014989B2 (en) * 2015-01-26 2021-05-25 Cellectis Anti-CLL1 specific single-chain chimeric antigen receptors (scCARs) for cancer immunotherapy
WO2017176760A2 (fr) * 2016-04-04 2017-10-12 Vladislav Sandler Procédé d'élimination de cellules souches hématopoïétique/progéniteurs hématopoïétiques (csh/ph) chez un patient à l'aide d'anticorps bispécifiques
WO2018193231A1 (fr) * 2017-04-18 2018-10-25 Autolus Limited Cellule

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180110832A1 (en) * 2015-04-20 2018-04-26 The Board Of Regents Of The University Of Texas Sy Stem Clec11a is a bone growth agent
WO2017219025A1 (fr) * 2016-06-17 2017-12-21 Magenta Therapeutics, Inc. Compositions et méthodes de déplétion de cellules

Also Published As

Publication number Publication date
CN114829399A (zh) 2022-07-29
WO2021007266A1 (fr) 2021-01-14
JP2022540602A (ja) 2022-09-16
CA3146912A1 (fr) 2021-01-14
EP3997128A1 (fr) 2022-05-18

Similar Documents

Publication Publication Date Title
EP3439699A4 (fr) Procédé d'élimination de cellules souches hématopoïétique/progéniteurs hématopoïétiques (csh/ph) chez un patient à l'aide d'anticorps bispécifiques
EP3924375A4 (fr) Cellules souches donnatrices universelles et méthodes associées
EP3914271A4 (fr) Compositions et procédés de génération de cellules souches hématopoïétiques (csh)
EP4029947A4 (fr) Procédé de production d'un concentré de protéines végétales
EP3933032A4 (fr) Procédé de culture tridimensionnelle pour la préparation à grande échelle de cellules souches
EP3980067A4 (fr) Protéine de fusion anticorps-interleukine et procédés d'utilisation
EP3969560A4 (fr) Dispositif microfluidique et procédé d'utilisation pour la culture cellulaire
EP4089822A4 (fr) Diaphragme de remplissage de lithium et procédé de préparation d'un diaphragme de remplissage de lithium
EP4051478A4 (fr) Système chirurgical simulé, vaisseau simulé, et leurs procédés de fabrication et composants associés
EP3970744A4 (fr) Injection stable de secukinumab et procédé pour sa préparation
EP3973048A4 (fr) Compositions et procédés pour la culture de cellules végétales
EP3831926A4 (fr) Système de culture cellulaire et procédé de production de masse cellulaire le mettant en oeuvre
EP4069298A4 (fr) Composition d'anticorps triaxiaux et son procédé de production et d'utilisation
IL294152A (en) A method for culturing hematopoietic stem cells
EP3976066A4 (fr) Procédés de production et de multiplication de cellules souches hématopoïétiques
EP3959996A4 (fr) Composition d'émulsion utilisant une protéine de stockage de semences et son procédé de production
EP3997128A4 (fr) Procédé d'élimination de cellules souches hématopoïétique/progéniteurs hématopoïétiques (csh/ph) chez un patient à l'aide d'anticorps bispécifiques
EP3785721A4 (fr) Formulation de filtrat de cellules souches et son procédé de préparation
EP4110900A4 (fr) Génération de cellules hématopoïétiques de type aorte-gonades-mésonephros à partir de cellules souches pluripotentes humaines dans un état défini
EP4065232A4 (fr) Cellules présentatrices d'antigène artificielles produisant des cytokines et un scfv anti-cd3
EP3985103A4 (fr) Cellules capables de se différencier en cellules constituant le placenta, et leur procédé de production
EP4074819A4 (fr) Procédé de préparation d'une cellule souche mésenchymateuse à partir d'une cellule souche pluripotente humaine et cellules souches mésenchymateuses ainsi préparées
EP3933022A4 (fr) Procédé de fabrication d'un récipient de culture, et récipient de culture
EP4051782A4 (fr) Milieu et procédés de culture d'organoïdes
EP4022041A4 (fr) Lymphocytes t contenant des nef et leurs méthodes de production

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220114

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/00 20060101ALI20230606BHEP

Ipc: A61P 37/06 20060101ALI20230606BHEP

Ipc: A61K 45/06 20060101ALI20230606BHEP

Ipc: A61K 39/395 20060101ALI20230606BHEP

Ipc: C07K 16/28 20060101AFI20230606BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20230914

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/00 20060101ALI20230908BHEP

Ipc: A61P 37/06 20060101ALI20230908BHEP

Ipc: A61K 45/06 20060101ALI20230908BHEP

Ipc: A61K 39/395 20060101ALI20230908BHEP

Ipc: C07K 16/28 20060101AFI20230908BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20240219